Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Pelican-Sim 1.0: A General World Model Simulator for Embodied Intelligence
arXiv:2609.12036v1 Announce Type: cross Abstract: In this technical report, we propose Pelican-Sim 1.0, a general world model simulator for embodied intelligence that predicts future observations from visual context and robot actions to support downstream learning and decision making. The model incorporates four key design features: (1) Unified action representation: a 28-dimensional action value space covering most mainstream embodiments, keeping one model valid across heterogeneous devices. (
-
cs.AI, q-bio.NC updates on arXiv.org
-
Diffusion learning reveals viable parameter manifolds and compensation geometry in biological dynamical systems
arXiv:2607.03671v2 Announce Type: replace-cross Abstract: Models of complex systems often have many parameters, yet are constrained by far fewer experimentally accessible observables; consequently, similar activity can emerge from coordinated parameter changes. We formalize these compatible parameter sets as \emph{viable parameter manifolds}: the inverse images of target dynamical features under a parameter-to-feature map. The relevant codimension is not the number of reported features, but the
Diffusion learning reveals viable parameter manifolds and compensation geometry in biological dynamical systems
-
Omics In Lung
-
Advanced and underlying therapeutic strategies in transformed small cell lung cancer
Front Med (Lausanne). 2026 Aug 27;13:1865050. doi: 10.3389/fmed.2026.1865050. eCollection 2026.ABSTRACTTransformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9-13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy
Advanced and underlying therapeutic strategies in transformed small cell lung cancer
Front Med (Lausanne). 2026 Aug 27;13:1865050. doi: 10.3389/fmed.2026.1865050. eCollection 2026.
ABSTRACT
Transformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9-13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy remains the gold standard for confirming histologic transformation, whereas molecular profiling and liquid biopsy may facilitate early detection and longitudinal disease monitoring. Platinum-etoposide remains the most commonly used clinical standard after transformation, but its benefit is typically transient and durable disease control remains uncommon. Continuation of EGFR tyrosine kinase inhibitors combined with chemotherapy may prolong progression-free survival in selected patients but has not consistently improved overall survival. Anti-angiogenic therapy, particularly anlotinib, and chemo-immunotherapy have shown encouraging activity in selected patients, while emerging strategies targeting DLL3, MYC, SOX2, and epigenetic regulators may broaden the therapeutic landscape. Prospective studies integrating repeat tissue sampling, comprehensive genomic profiling, biomarker-guided patient stratification, pharmacogenomics, functional drug-sensitivity testing where feasible, and integrated multi-omics approaches are needed to advance molecularly guided and individualized treatment for T-SCLC.
PMID:42724635 | PMC:PMC13560167 | DOI:10.3389/fmed.2026.1865050